An Open Label Extension Study to Assess the Safety and Tolerability of PBT2, and its Effect on Amyloid Deposition in the Brains of Patients with Prodromal or Mild Alzheimer's Disease. [EXTENSION OF 700196942].

Trial Profile

An Open Label Extension Study to Assess the Safety and Tolerability of PBT2, and its Effect on Amyloid Deposition in the Brains of Patients with Prodromal or Mild Alzheimer's Disease. [EXTENSION OF 700196942].

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs PBT 2 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms IMAGINE Extension
  • Sponsors Prana Biotechnology
  • Most Recent Events

    • 30 Jun 2015 According to a Prana Biotechnology media release, the safety data from this trial will form part of the package presented to the FDA to remove the Partial Clinical Hold on PBT2 in the US.
    • 30 Jun 2015 According to a Prana Biotechnology media release, the independent Data Safety Monitoring Board did not identify any safety concerns. Out of 33 a total of 27 patients completed the this Extension Study.
    • 30 Jun 2015 Safety results published in the Prana Biotechnology Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top